These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33852862)

  • 1. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.
    Murin CD; Gilchuk P; Ilinykh PA; Huang K; Kuzmina N; Shen X; Bruhn JF; Bryan AL; Davidson E; Doranz BJ; Williamson LE; Copps J; Alkutkar T; Flyak AI; Bukreyev A; Crowe JE; Ward AB
    Cell Rep; 2021 Apr; 35(2):108984. PubMed ID: 33852862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk.
    King LB; West BR; Moyer CL; Gilchuk P; Flyak A; Ilinykh PA; Bombardi R; Hui S; Huang K; Bukreyev A; Crowe JE; Saphire EO
    Nat Commun; 2019 Apr; 10(1):1788. PubMed ID: 30996276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
    Misasi J; Gilman MS; Kanekiyo M; Gui M; Cagigi A; Mulangu S; Corti D; Ledgerwood JE; Lanzavecchia A; Cunningham J; Muyembe-Tamfun JJ; Baxa U; Graham BS; Xiang Y; Sullivan NJ; McLellan JS
    Science; 2016 Mar; 351(6279):1343-6. PubMed ID: 26917592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
    Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
    Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.
    Murin CD; Gilchuk P; Crowe JE; Ward AB
    Front Immunol; 2021; 12():808047. PubMed ID: 35082794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
    Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
    J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.
    Gilchuk P; Murin CD; Milligan JC; Cross RW; Mire CE; Ilinykh PA; Huang K; Kuzmina N; Altman PX; Hui S; Gunn BM; Bryan AL; Davidson E; Doranz BJ; Turner HL; Alkutkar T; Flinko R; Orlandi C; Carnahan R; Nargi R; Bombardi RG; Vodzak ME; Li S; Okoli A; Ibeawuchi M; Ohiaeri B; Lewis GK; Alter G; Bukreyev A; Saphire EO; Geisbert TW; Ward AB; Crowe JE
    Immunity; 2020 Feb; 52(2):388-403.e12. PubMed ID: 32023489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
    Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA
    Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity.
    Wirchnianski AS; Wec AZ; Nyakatura EK; Herbert AS; Slough MM; Kuehne AI; Mittler E; Jangra RK; Teruya J; Dye JM; Lai JR; Chandran K
    Front Immunol; 2021; 12():729851. PubMed ID: 34721393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
    Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
    Front Immunol; 2021; 12():706757. PubMed ID: 34335620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.
    Flyak AI; Kuzmina N; Murin CD; Bryan C; Davidson E; Gilchuk P; Gulka CP; Ilinykh PA; Shen X; Huang K; Ramanathan P; Turner H; Fusco ML; Lampley R; Kose N; King H; Sapparapu G; Doranz BJ; Ksiazek TG; Wright DW; Saphire EO; Ward AB; Bukreyev A; Crowe JE
    Nat Microbiol; 2018 Jun; 3(6):670-677. PubMed ID: 29736037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.
    Audet J; Wong G; Wang H; Lu G; Gao GF; Kobinger G; Qiu X
    Sci Rep; 2014 Nov; 4():6881. PubMed ID: 25375093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
    Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-ebolavirus protective therapy by two multifunctional human antibodies.
    Gilchuk P; Murin CD; Cross RW; Ilinykh PA; Huang K; Kuzmina N; Borisevich V; Agans KN; Geisbert JB; Zost SJ; Nargi RS; Sutton RE; Suryadevara N; Bombardi RG; Carnahan RH; Bukreyev A; Geisbert TW; Ward AB; Crowe JE
    Cell; 2021 Oct; 184(22):5593-5607.e18. PubMed ID: 34715022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge.
    Chen G; Koellhoffer JF; Zak SE; Frei JC; Liu N; Long H; Ye W; Nagar K; Pan G; Chandran K; Dye JM; Sidhu SS; Lai JR
    ACS Chem Biol; 2014 Oct; 9(10):2263-73. PubMed ID: 25140871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap.
    Ilinykh PA; Santos RI; Gunn BM; Kuzmina NA; Shen X; Huang K; Gilchuk P; Flyak AI; Younan P; Alter G; Crowe JE; Bukreyev A
    PLoS Pathog; 2018 Aug; 14(8):e1007204. PubMed ID: 30138408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
    West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO
    mBio; 2018 Sep; 9(5):. PubMed ID: 30206174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
    Lennemann NJ; Rhein BA; Ndungo E; Chandran K; Qiu X; Maury W
    mBio; 2014 Jan; 5(1):e00862-13. PubMed ID: 24473128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Insights into Reovirus σ1 Interactions with Two Neutralizing Antibodies.
    Dietrich MH; Ogden KM; Katen SP; Reiss K; Sutherland DM; Carnahan RH; Goff M; Cooper T; Dermody TS; Stehle T
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.